Johnson & Johnson (JNJ): Price and Financial Metrics

Johnson & Johnson (JNJ): $164.08

0.36 (+0.22%)

POWR Rating

Component Grades














  • Stability is the dimension where JNJ ranks best; there it ranks ahead of 94.84% of US stocks.
  • JNJ's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • JNJ's current lowest rank is in the Momentum metric (where it is better than 18.97% of US stocks).

JNJ Stock Summary

  • Johnson & Johnson's market capitalization of $430,147,573,833 is ahead of 99.72% of US-listed equities.
  • Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.68% of US equities in our set.
  • The volatility of Johnson & Johnson's share price is greater than that of just 0.68% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Johnson & Johnson, a group of peers worth examining would be UNH, BAC, WMT, ADBE, and NFLX.
  • JNJ's SEC filings can be seen here. And to visit Johnson & Johnson's official web site, go to

JNJ Valuation Summary

  • JNJ's EV/EBIT ratio is 23.3; this is 20.48% lower than that of the median Healthcare stock.
  • Over the past 243 months, JNJ's price/sales ratio has gone down 1.
  • Over the past 243 months, JNJ's price/sales ratio has gone down 1.

Below are key valuation metrics over time for JNJ.

Stock Date P/S P/B P/E EV/EBIT
JNJ 2021-08-31 5.1 6.6 25.7 23.3
JNJ 2021-08-30 5.1 6.6 25.7 23.4
JNJ 2021-08-27 5.1 6.5 25.6 23.3
JNJ 2021-08-26 5.1 6.6 25.7 23.3
JNJ 2021-08-25 5.1 6.6 25.8 23.5
JNJ 2021-08-24 5.2 6.6 26.0 23.6

JNJ Growth Metrics

  • The 5 year cash and equivalents growth rate now stands at 13.09%.
  • Its year over year cash and equivalents growth rate is now at -18.41%.
  • The 3 year net income to common stockholders growth rate now stands at -4.56%.
JNJ's revenue has moved up $16,659,000,000 over the prior 49 months.

The table below shows JNJ's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 89,190 26,114 17,767
2021-03-31 84,214 24,252 15,115
2020-12-31 82,584 23,536 14,714
2020-09-30 80,856 21,591 16,986
2020-06-30 80,503 20,735 15,185
2020-03-31 82,729 23,231 17,166

JNJ's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • JNJ has a Quality Grade of B, ranking ahead of 92.72% of graded US stocks.
  • JNJ's asset turnover comes in at 0.514 -- ranking 81st of 681 Pharmaceutical Products stocks.
  • ACRX, BCDA, and ABBV are the stocks whose asset turnover ratios are most correlated with JNJ.

The table below shows JNJ's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-04 0.514 0.670 0.302
2021-04-04 0.498 0.662 0.273
2021-01-03 0.501 0.656 0.272
2020-09-27 0.504 0.657 0.332
2020-06-28 0.514 0.657 0.307
2020-03-29 0.531 0.662 0.372

JNJ Price Target

For more insight on analysts targets of JNJ, see our JNJ price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $187.95 Average Broker Recommendation 1.53 (Moderate Buy)

JNJ Stock Price Chart Interactive Chart >

Price chart for JNJ

JNJ Price/Volume Stats

Current price $164.08 52-week high $179.92
Prev. close $163.72 52-week low $133.65
Day low $161.71 Volume 6,715,300
Day high $164.31 Avg. volume 7,012,728
50-day MA $167.07 Dividend yield 2.59%
200-day MA $165.81 Market Cap 431.94B

Johnson & Johnson (JNJ) Company Bio

Founded in 1886, Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture, and sale of products in the healthcare field within its Consumer, Pharmaceutical and Medical Devices segments. The Consumer segment consists of skin and self-care product brand names such as Aveeno, Neutrogena, Rogaine, Tylenol, Motrin, Listerine, and Band-Aid. Johnson’s Pharmaceutical segment contains biopharma products that address immune, cardiovascular, metabolic, and infectious disease medical conditions. The Medical Device segment develops products centered around orthopedic, surgical, intervention, and vision solutions. The company has over 130,000 employees worldwide and is headquartered in New Brunswick, New Jersey. The company’s current Chief Executive Officer is Alex Gorsky.

JNJ Latest News Stream

Event/Time News Detail
Loading, please wait...

JNJ Latest Social Stream

Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

'We're definitely not doing enough' to help global vaccinations: Former US Commerce Sec.

Former U.S. Commerce Sec. Gary Locke weighs in on the global vaccine equity debate and how the U.S. can better respond to the ongoing pandemic.

Yahoo | October 22, 2021

Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters

Vaccine stocks mostly fell Friday after the CDC authorized Moderna, J&J boosters, plus a mix-and-match strategy for Covid booster shots.

Yahoo | October 22, 2021

Logistics and distribution key to fighting COVID-19 worldwide, says former commerce secretary.

Gary Locke, former U.S. Commerce Secretary, talks vaccine distribution, intellectual property, and why cold storage and personnel are critical to fighting COVID-19 around the world.

Yahoo | October 22, 2021

Pfizer says vaccine is 90.7% effective in kids aged 5 to 11: BBG

Dr. Calvin Sun, The Monsoon Diaries Founder & CEO, Clinical Assistant Professor and Attending Physician in Emergency Medicine in NYC, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Yahoo | October 22, 2021

EXPLAINER-Americans wonder: Which COVID-19 booster is best?

The U.S. Centers for Disease Control and Prevention (CDC) on Thursday said individuals who qualify could choose a different vaccine from the one they received for their initial inoculation. The CDC now recommends that everyone 18 and older who got the Johnson & Johnson vaccine at least two months earlier should receive any one of the authorized COVID-19 boosters. Those who got either of the messenger RNA (mRNA) vaccines from Pfizer/BioNTech or Moderna who are 65 or older are eligible for a booster.

Yahoo | October 22, 2021

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo -0.17%
3-mo -4.14%
6-mo 1.15%
1-year 16.89%
3-year 29.68%
5-year 61.87%
YTD 6.19%
2020 10.82%
2019 16.22%
2018 -5.13%
2017 24.43%
2016 15.33%

JNJ Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8306 seconds.